HRM method for identification of TP53 exon 5 and 8 mutations in human prostate cancer patients

Basit Öğe Kaydı
dc.authoridCakir, Suleyman Sami/0000-0002-0211-3450
dc.contributor.authorOzmerdiven, Cagdas Gokhun
dc.contributor.authorDirican, Ebubekir
dc.contributor.authorAyan, Semih
dc.contributor.authorTatar, Zeynep
dc.contributor.authorCakir, Sami
dc.contributor.authorGuler, Yavuz
dc.contributor.authorKaradag, Abdullah
dc.date.accessioned2024-10-04T18:51:05Z
dc.date.available2024-10-04T18:51:05Z
dc.date.issued2022
dc.departmentBayburt Üniversitesien_US
dc.description.abstractBackground: The purpose of the present study was to perform a high-resolution melting (HRM) analysis to discover mutations in gene exons 5-8 of tumor protein p53 (TP53), as well as the relationships of these mutations to clinical parameters in prostate cancer (PC).& nbsp;Methods: Genomic DNA was extracted from 50 formalin-fixed paraffin-embedded (FFPE) tissues with PC. Mutations in exons 5 and 8 of TP53 were analyzed using the HRM method. Sanger sequencing was used to describe mutations.& nbsp;Results: According to the HRM analysis results, 21 (42%) PC samples had different normalized and shifted melting curves from other samples. Mutations in TP53 exons 5 and8 were observed in 12 (24%) patients by the Sanger method. The detection sensitivity of the HRM method in exon 5 and exon 8 mutations was 66.7% and 50%, respectively. PSA levels of PC patients with TP53 mutation were found to be lower than that of patients with no mutation (p = 0.8270). However, we did not find any correlations between TP53 mutations and clinical parameters (p > 0.05).& nbsp;Conclusions: HRM analysis is a simple, rapid, and efficient mutation-scanning method for known/unknown mutations in TP53 exons 5and8, as well as an attractive method for detection of mutations and their analysis in FFPE tissues. Additional studies with larger patient populations are warranted to confirm the correlation between the TP53 mutations and PC risk.en_US
dc.description.sponsorshipResearch Foundation of Istanbul Aydin University (BAP) [2019/6-10311]en_US
dc.description.sponsorshipThis work was supported by grants (2019/6-10311 to C.G.O.) from the Research Foundation of Istanbul Aydin University (BAP).en_US
dc.identifier.doi10.1016/j.mgene.2022.101020
dc.identifier.issn2214-5400
dc.identifier.scopus2-s2.0-85149372538en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.urihttps://doi.org/10.1016/j.mgene.2022.101020
dc.identifier.urihttp://hdl.handle.net/20.500.12403/3373
dc.identifier.volume31en_US
dc.identifier.wosWOS:000792756700012en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofMeta Geneen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHRMen_US
dc.subjectProstate canceren_US
dc.subjectSangeren_US
dc.subjectFFPEen_US
dc.subjectTP53en_US
dc.subjectPCRen_US
dc.titleHRM method for identification of TP53 exon 5 and 8 mutations in human prostate cancer patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu